Significant @entity5 shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in XXXX .

@entity1 @entity5 @entity442 @entity2012 @entity4841
OBJECTIVE: To evaluate GH and @entity442 control and @entity5 shrinkage in newly diagnosed @entity1 with @entity2012 treated first-line with lanreotide-Autogel (ATG) 120 mg. Design Open, prospective. @entity1 : Twenty-six @entity1 (17 @entity1 , aged 31-70 years): eight enclosed and 12 extrasellar (eight invasive) macroadenomas and six microadenomas (one invasive). ATG 120 mg initially given every 4 weeks for 12 weeks; then intervals between injections increased to every 6 or 8 weeks if GH levels were <or= 2.5 or < 1 microg/l (equal to 6.5 and 2.6 mU/l), respectively. RESULTS: Final dosage was ATG 120 mg every 4 weeks in nine @entity1 (34.6%), every 6 weeks in eight @entity1 (30.8%) and every 8 weeks in the remaining nine @entity1 (34.6%). After 12 months, both GH and @entity442 were controlled in 14 @entity1 (53.8%). The mean @entity5 volume decreased from 1405 +/- 1827 mm(3) at study entry to 960 +/- 1381 mm(3) after 6 months, and 799 +/- 1161 mm(3) after 12 months (P < 0.0001). Overall @entity5 shrinkage was 35.8 +/- 28.1% after 6 months and 48.4 +/- 27.6% after 12 months. After 12 months, 20 @entity1 (76.9%) achieved > 25% @entity5 shrinkage: 12 of 14 with controlled disease (85.7%) and 8 of 12 with noncontrolled disease (66.7%; P = 0.49). Hyperhydrosis, paresthesiae and @entity4841 significantly reduced after treatment. No @entity1 withdrew from the study because of adverse events. CONCLUSION: ATG 120 mg in newly diagnosed @entity1 with @entity2012 controls GH and @entity442 secretion in 53.8% and induces >or= 25% @entity5 shrinkage in 76.9% during a 12-month period. The treatment was associated with improvement of clinical symptoms and with a good safety profile.
